A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease (ExpeditionPRO)

H8A-MC-LZBE -

The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's Disease (AD).

Trial Summary

Age Range
55 - 85 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
Yes
Enrollment Goal
26
Trial Dates
Jun 1, 2016 - May 1, 2017
How long will I be in the trial?
Your participation could last up to 28 months and include 29 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.